FAILED TRIALS: Ph 3 trials, LEAP-006 and LEAP-008, of KEYTRUDA + LENVIMA in patients with certain types of mNSCLC did not meet primary endpoints of OS & PFS September 26, 2023
PADCEV and KEYTRUDA Significantly Improve OS and PFS in Patients With Previously Untreated Advanced Bladder Cancer in Ph 3 EV-302 Trial September 26, 2023
Yescarta Demonstrates High Response Rate And Durable Remission In ALYCANTE Study As Initial Treatment For Transplant-Ineligible Patients With R/R LBCL September 26, 2023
Datopotamab deruxtecan demonstrated statistically significant PFS benefit in patients with HR+ve, HER2-low/neg breast cancer in TROPION-Breast01 Ph 3 trial September 26, 2023
Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves EFS in Patients with Resectable NSCLC September 26, 2023
Ph 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of OS and PFS in Certain Patients With 1L Locally Advanced or Metastatic Urothelial Cancer September 26, 2023
Ph 2 EVOKE-02 Study Of Trodelvy + KEYTRUDA Demonstrates Promising Clinical Activity In 1L mNSCLC September 19, 2023
Datopotamab deruxtecan + Imfinzi showed promising clinical activity in 1L advanced NSCLC in TROPION-Lung04 Ph 1b trial September 19, 2023
Enhertu demonstrated strong and durable tumor responses in previously treated HER2-mutant advanced lung cancer in DESTINY-Lung02 Ph 2 trial September 19, 2023
New Lumakras® (Sotorasib) Plus Chemotherapy Data In First-Line KRAS G12C NSCLC announced September 19, 2023
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated mNSCLC in HERTHENA-Lung01 Ph 2 Trial September 19, 2023
TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved OS in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy September 13, 2023
Ph 3 MARIPOSA-2 Study Meets Dual Primary Endpoint Resulting in PFS Improvement with RYBREVANT + Chemo +/- Lazertinib vs chemo Alone in Patients with EGFR-Mutated NSCLC after Disease Progression on Osimertinib September 13, 2023
Positive outcome of the prespecified interim futility analysis for Ph 2b ASCEND trial of LSTA1 + SOC in patients with 1L mPDAC announced September 13, 2023
Datopotamab deruxtecan plus Imfinzi showed promising clinical activity in the 1L advanced NSCLC setting in TROPION-Lung04 Phase Ib trial September 13, 2023
Tagrisso plus chemotherapy extended mPFS by nearly 9 months in EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial September 13, 2023
Phase III ALINA study of Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) September 6, 2023
FAILED TRIAL: Ph 3 INNOVATE-3 trial of TTFields + paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of OS September 6, 2023
Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Announced September 6, 2023
Positive Results from Ph 3 CONTACT-02 Trial of Cabozantinib + Atezolizumab in metastatic CRPC Announced September 6, 2023
Retevmo® (selpercatinib) Demonstrates Superior PFS Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer September 6, 2023
FAILED TRIAL: Phase 3 LEAP-010 Trial of LENVIMA + KEYTRUDA in Patients With Certain Types of Recurrent or mSCCHN unlikely to meet primary endpoint of OS September 6, 2023
Ph 3 Trial of TUKYSA + ado-trastuzumab emtansine Meets Primary Endpoint of PFS in Patients with Previously Treated HER2+ve Metastatic Breast Cancer August 23, 2023
WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced RCC August 23, 2023
